

Dellann Elliott Mydland - Patient Advocate and Business Leader

Due to her personal experience with brain cancer, Dellann has worked tirelessly on behalf of cancer & brain tumor patients, caregivers and their families for over 20 years since co-founding the Chris Elliott Fund, now doing business as the EndBrainCancer Initiative (EBCI). Dellann is, at once, a patient advocate, entrepreneur, educator, mentor, visionary, and creator of a unique “Customer Support Type of Advocacy/Disease Education, Awareness & Outreach Program/Service” & the “Direct Connect” Referral Program/Service model, that other Advocacy organizations have and are now replicating which has an emphasis on 1:1 personalized delivery of disease education, and “direct connect” via text/email and phone connections to specialists, 2nd options and clinical trial access. This model benefits patients and their families while also benefiting the research community alike, in that it directly connects newly diagnosed, recurrent and metastatic brain cancer patients across the country with top brain tumor neurosurgeons, neuro-oncologists, radiation oncologists, principal investigators/researchers, genomic & molecular profiling (Next Generation Sequencing), advanced treatments, clinical trials, targeted treatments, immunology/vaccines, and personalized medicine. This approach ultimately creates greater Quality of Life for the patient, increases research data, increases treatment options and improves Standard of Care (SOC) for all, therefore, improving survivorship.



Dellann “views IMMEDIATE ACCESS to all of the above as essential for providing HOPE to the brain tumor patient and rare disease communities, improving patient outcomes & quality of life, advancing research, improving clinical trial development access as well as improving Standard of Care and Clinical Practice for all cancer patients.”

Dellann is a skilled public advocate, testifying at hearings for new treatment options/FDA approval and proper reimbursement coding for treatments/devices, etc. in Washington, D.C. and around the country, educating legislatures, doctors and patients personally and through multimedia disease educational campaigns while driving collaboration within the research community at all junctures. She is a regular contributor to leading brain tumor and oncology patient awareness and education publications, including peer reviewed publications and actively participates as a Patient Advocate providing the “Patient Voice” for cancer and brain cancer clinical trials to multiple Clinical Trial Organizations (CRO’s), Drug/Device/NGS, City of Hope, California Institute for Regenerative Medicine, John Hopkins, Yale, etc., clinical trial sponsors and Institutions while also sitting on multiple Patient Advocacy Industry Boards. Dellann actively

advocates on behalf of patients with brain cancer responding to Advocacy opportunities for improved access to CMS/Medicare and health insurance coverage, FDA new treatment option approvals, improvements to FDA's clinical trial approval process to include a more diverse group of participants as well as coverage related to advanced diagnostics, such as Next Generation Genomic Sequencing. Dellann most recently served as the brain cancer patient advocate for NRG Oncology on both the neuro/clinical trial and neuro-surgery committees. In addition, Dellann has consulted as a patient advocate on multiple pediatric and adult brain cancer patient clinical trials for Genentech, Arbor Pharmaceuticals, Novocure, etc. as well as has been named on several research project applications to NCI/NIH as the brain tumor Patient Advocate of choice and has created/edited multiple patient disease educational brochures/websites/videos, etc. on behalf of the pharmaceuticals industry. Dellann is a past recipient of the National Brain Cancer Advocate HOPE Award and was chosen by Harvard and Dana-Farber Cancer Institute as their choice for patient advocate for a GBM "Stand-Up to Cancer" funded research project. Dellann's leads her organization's "NCI-CONNECT" clinical trial education/outreach program & partnership efforts as well as EBCI's patient/caregiver referral "Direct Connect" program and partnership efforts with the Brain Tumor Network (BTN). In addition, she serves on multiple pharma/industry Patient Advocacy Boards and is a member of the Society of Neuro-oncology (SNO), American Association Clinical Research (AACR), among others. Her consultation fee is \$275/hour.

A Bachelor's in Education, multiple business classes such as Accounting, Business Law, Public Speaking, Economics, etc., non-profit management courses & experience, marketing and sales background as well as her many years in regulatory coordination and management and a crash course on GBM treatments/science/clinical trials/next generation sequencing, etc. make Dellann uniquely qualified as EBCI's CEO, President & Board Chair to lead EBCI's mission, Board and Team, teach advocacy, program and the "patient voice" as well as develop and manage disease education programming, including all aspects of awareness & outreach as well excelling at hosting and leading interviews and online disease education programming, meetings and events for the last 20 years.

To learn more about Dellann's work, the EndBrainCancer Initiative's focus, day-to-day work and IMPACT as well as how to best partner on mutual goals, visit www.EndBrainCancer.org to learn more/fill out a "Corporate Partner Form" or contact her directly at Dellann@EndBrainCancer.org, 425-785-8489.

Dellann also serves as a paid advisor on AdvisoryCloud.

Additional information related to Dellann's Advocacy, Leadership, Inspiration and IMPACT efforts and experience can be found on/at:

LinkedIn

Corporate Magazine Feature: Profile link: <https://thecorporatemagazine.com/making-a-difference-in-healthcare-dellann-elliott-mydland/>

Magazine link: <https://thecorporatemagazine.com/Magazine/TCM/August2022.html>